CN110606826A - 托拉塞米钠一水合物、其晶型及组合物 - Google Patents
托拉塞米钠一水合物、其晶型及组合物 Download PDFInfo
- Publication number
- CN110606826A CN110606826A CN201910435040.1A CN201910435040A CN110606826A CN 110606826 A CN110606826 A CN 110606826A CN 201910435040 A CN201910435040 A CN 201910435040A CN 110606826 A CN110606826 A CN 110606826A
- Authority
- CN
- China
- Prior art keywords
- torasemide
- sodium
- sodium monohydrate
- acetone
- monohydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BQHGMQPPSXPREC-UHFFFAOYSA-M sodium;[4-(3-methylanilino)pyridin-3-yl]sulfonyl-(propan-2-ylcarbamoyl)azanide Chemical compound [Na+].CC(C)NC(=O)[N-]S(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 BQHGMQPPSXPREC-UHFFFAOYSA-M 0.000 title claims abstract description 60
- 239000013078 crystal Substances 0.000 title abstract description 13
- 239000000203 mixture Substances 0.000 title abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 27
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 44
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 12
- 238000001953 recrystallisation Methods 0.000 claims description 9
- 229940125782 compound 2 Drugs 0.000 claims description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000001882 diuretic effect Effects 0.000 claims description 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 239000002934 diuretic Substances 0.000 claims description 5
- 239000002585 base Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 229960005461 torasemide Drugs 0.000 description 37
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 34
- 238000003756 stirring Methods 0.000 description 18
- 238000010438 heat treatment Methods 0.000 description 17
- 238000001914 filtration Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- 235000011121 sodium hydroxide Nutrition 0.000 description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 11
- 229910052708 sodium Inorganic materials 0.000 description 11
- 229940083542 sodium Drugs 0.000 description 11
- -1 torasemide lithium salt Chemical class 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000007787 solid Substances 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- 229940126214 compound 3 Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 239000012452 mother liquor Substances 0.000 description 6
- 238000000113 differential scanning calorimetry Methods 0.000 description 5
- 229910003002 lithium salt Inorganic materials 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 229960000281 trometamol Drugs 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- ZXPCUGWAKUIOOF-UHFFFAOYSA-N 4-(3-methylanilino)pyridine-3-sulfonamide Chemical compound CC1=CC=CC(NC=2C(=CN=CC=2)S(N)(=O)=O)=C1 ZXPCUGWAKUIOOF-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000007333 Brain Concussion Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- ZQNPDAVSHFGLIQ-UHFFFAOYSA-N calcium;hydrate Chemical compound O.[Ca] ZQNPDAVSHFGLIQ-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- FZRNJOXQNWVMIH-UHFFFAOYSA-N lithium;hydrate Chemical compound [Li].O FZRNJOXQNWVMIH-UHFFFAOYSA-N 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- RJUVFGTVVVYSFK-UHFFFAOYSA-N phenyl n-propan-2-ylcarbamate Chemical compound CC(C)NC(=O)OC1=CC=CC=C1 RJUVFGTVVVYSFK-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (13)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910435040.1A CN110606826B (zh) | 2019-05-23 | 2019-05-23 | 托拉塞米钠一水合物、其晶型及组合物 |
PCT/CN2020/084801 WO2020233288A1 (zh) | 2019-05-23 | 2020-04-14 | 托拉塞米钠一水合物、其晶型及组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910435040.1A CN110606826B (zh) | 2019-05-23 | 2019-05-23 | 托拉塞米钠一水合物、其晶型及组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110606826A true CN110606826A (zh) | 2019-12-24 |
CN110606826B CN110606826B (zh) | 2021-06-01 |
Family
ID=68889634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910435040.1A Active CN110606826B (zh) | 2019-05-23 | 2019-05-23 | 托拉塞米钠一水合物、其晶型及组合物 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110606826B (zh) |
WO (1) | WO2020233288A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020233288A1 (zh) * | 2019-05-23 | 2020-11-26 | 上海勋和医药科技有限公司 | 托拉塞米钠一水合物、其晶型及组合物 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4861786A (en) * | 1986-07-12 | 1989-08-29 | Boehringer Mannheim Gmbh | Composition for a stable vein compatible injectable solution of torasemide process for the preparation and method of use |
US4910126A (en) * | 1987-04-10 | 1990-03-20 | Konica Corporation | Light-sensitive silver halide color photographic material |
US5486530A (en) * | 1991-04-27 | 1996-01-23 | Boehringer Mannheim Gmbh | Use of torasemide for the treatment of brain oedemas |
WO2003097603A1 (en) * | 2002-05-21 | 2003-11-27 | Finetech Laboratories Ltd. | Process for the preparation of highly pure torsemide |
US20050209460A1 (en) * | 2004-03-16 | 2005-09-22 | Brantford Chemicals Inc. | Process for the preparation of torsemide and related intermediates |
AT505929A4 (de) * | 2008-04-07 | 2009-05-15 | Univ Wien Tech | Torasemid |
CN102702089A (zh) * | 2012-06-30 | 2012-10-03 | 连云港杰瑞药业有限公司 | 一种高纯度托拉塞米及其晶型i的制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110606826B (zh) * | 2019-05-23 | 2021-06-01 | 上海勋和医药科技有限公司 | 托拉塞米钠一水合物、其晶型及组合物 |
-
2019
- 2019-05-23 CN CN201910435040.1A patent/CN110606826B/zh active Active
-
2020
- 2020-04-14 WO PCT/CN2020/084801 patent/WO2020233288A1/zh active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4861786A (en) * | 1986-07-12 | 1989-08-29 | Boehringer Mannheim Gmbh | Composition for a stable vein compatible injectable solution of torasemide process for the preparation and method of use |
US4910126A (en) * | 1987-04-10 | 1990-03-20 | Konica Corporation | Light-sensitive silver halide color photographic material |
US5486530A (en) * | 1991-04-27 | 1996-01-23 | Boehringer Mannheim Gmbh | Use of torasemide for the treatment of brain oedemas |
WO2003097603A1 (en) * | 2002-05-21 | 2003-11-27 | Finetech Laboratories Ltd. | Process for the preparation of highly pure torsemide |
US20050209460A1 (en) * | 2004-03-16 | 2005-09-22 | Brantford Chemicals Inc. | Process for the preparation of torsemide and related intermediates |
AT505929A4 (de) * | 2008-04-07 | 2009-05-15 | Univ Wien Tech | Torasemid |
CN102702089A (zh) * | 2012-06-30 | 2012-10-03 | 连云港杰瑞药业有限公司 | 一种高纯度托拉塞米及其晶型i的制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020233288A1 (zh) * | 2019-05-23 | 2020-11-26 | 上海勋和医药科技有限公司 | 托拉塞米钠一水合物、其晶型及组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN110606826B (zh) | 2021-06-01 |
WO2020233288A1 (zh) | 2020-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110606860B (zh) | 一种吡啶磺酰胺磷酸酯类化合物、其制备方法及其用途 | |
JP2001058976A (ja) | ラクタムフリーのアミノ酸 | |
US11013736B2 (en) | Oral solid preparation and use thereof | |
AU2013330603B2 (en) | Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same | |
BRPI0706062A2 (pt) | rosuvastatina cálcica cristalina | |
WO2009017813A1 (en) | O-desmethyl venlafaxine saccharinate | |
US10611757B2 (en) | Crystalline form of chemical compound, and preparation method, composition, and application thereof | |
CN114026085A (zh) | (e)-3-[2-(2-噻吩基)乙烯基]-1h-吡唑的固体形式 | |
JP2023122634A (ja) | トリエチレンテトラミン四塩酸塩、その製造方法及び組成物 | |
JP2008516001A (ja) | 非晶質、および多形のフォームのテルミサルタン・ナトリウム | |
CN110606826B (zh) | 托拉塞米钠一水合物、其晶型及组合物 | |
JP2755918B2 (ja) | テラゾシンモノヒドロクロリド及びその製造法並びに該化合物を製造するための中間体 | |
CN110054647B (zh) | 托拉塞米磷酸酯类前药、其制备方法及组合物 | |
JP2013528206A (ja) | 結晶形態のサリドマイド及びその調製方法 | |
US20100256207A1 (en) | Amorphous olmesartan medoxomil | |
JP2569060B2 (ja) | グルタミルシスティン誘導体、その製造法およびそれを有効成分とする組織グルタチオンレベル向上剤 | |
KR102544543B1 (ko) | L,d-엘도스테인의 개별적 공결정화물 | |
JPS63264549A (ja) | 乳酸カルシウム‐グリセロール付加物およびその製法 | |
JP3931884B2 (ja) | 錠剤の製造方法 | |
CN110740988A (zh) | 制备l-鸟氨酸苯乙酸盐的方法 | |
KR20070088783A (ko) | 조 칸데사르탄 실렉세틸의 제조 | |
WO2008105794A1 (en) | Process for the purification of carvedilol or its salts thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 200000 room 216, building 2, No. 1366, Qishen Road, Minhang District, Shanghai Patentee after: Shanghai Xunhe Pharmaceutical Technology Co.,Ltd. Address before: 200000 Shanghai Xunhe Pharmaceutical Technology Co., Ltd., 5 / F, building 2, 1295 chuanqiao Road, Pudong New Area, Shanghai Patentee before: Shanghai Xunhe Pharmaceutical Technology Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Tolasemide sodium monohydrate, its crystal form and composition Granted publication date: 20210601 Pledgee: Chengdu Xietong Huida Biotechnology Development Co.,Ltd. Pledgor: Shanghai Xunhe Pharmaceutical Technology Co.,Ltd. Registration number: Y2024510000070 |